Literature DB >> 24114483

Functions, aberrations, and advances for chromatin modulation in cancer.

Mariarosaria Conte1, Lucia Altucci.   

Abstract

Cancer initiation and progression is causally connected to genome and epigenome deregulations. Epigenetic deregulations (such as DNA methylation, histone modifications, and miRNA-based modulation) have been increasingly reported in tumorigenesis and different chromatin-modulating enzymes have been discovered and classified and their aberrations connected to cancer. A better insight into alterations occurring on chromatin enzymes and their impact in cancer thus represents a crucial step in exploiting epigenetic targeting in cancer prevention and treatment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24114483     DOI: 10.1007/978-3-642-38007-5_13

Source DB:  PubMed          Journal:  Cancer Treat Res        ISSN: 0927-3042


  4 in total

1.  PePr: a peak-calling prioritization pipeline to identify consistent or differential peaks from replicated ChIP-Seq data.

Authors:  Yanxiao Zhang; Yu-Hsuan Lin; Timothy D Johnson; Laura S Rozek; Maureen A Sartor
Journal:  Bioinformatics       Date:  2014-06-03       Impact factor: 6.937

2.  JMJD5 is a potential oncogene for colon carcinogenesis.

Authors:  Ru Zhang; Qingjun Huang; Yinpeng Li; Yang Song; Yingxue Li
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

3.  HDAC2 deregulation in tumorigenesis is causally connected to repression of immune modulation and defense escape.

Authors:  Mariarosaria Conte; Carmela Dell'Aversana; Rosaria Benedetti; Francesca Petraglia; Annamaria Carissimo; Valeria Belsito Petrizzi; Alfonso Maria D'Arco; Ciro Abbondanza; Angela Nebbioso; Lucia Altucci
Journal:  Oncotarget       Date:  2015-01-20

4.  Histone deacetylase 2 knockout suppresses immune escape of triple-negative breast cancer cells via downregulating PD-L1 expression.

Authors:  Pengfei Xu; Wei Xiong; Yun Lin; Liping Fan; Hongchao Pan; Yaochen Li
Journal:  Cell Death Dis       Date:  2021-08-07       Impact factor: 8.469

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.